Results

Total Results: 536 records

Showing results for "statin".
Users also searched for: statin

241. Ch 5-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_5-user-guide-to-ocer_130129.pdf
     January 01, 2012 - For example, in a study assessing the risk of cancer in statin use,4 users of glaucoma drugs (like … patients5), were employed as an active comparison group with an aim to control for potential bias due to statin

242. Microsoft PowerPoint - pharmacy-data.ppt [Compatibility Mode] (pdf file)
     hcup-us.ahrq.gov/datainnovations/clinicalcontentenhancementtoolkit/mn5.pdf
     June 21, 2014 - Microsoft PowerPoint - pharmacy-data.ppt [Compatibility Mode] “Using Clinically Enhanced“Using Clinically-Enhanced Claims Data to Guide Treatment of Acute Heart Failure” An AHRQ Grant to MHA Data Acquisition & Transmission Pharmacy Data Overview of Data Acquisition Strategyq gy • Establish data specification…

243. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cognitive-decline_executive.pdf
     March 01, 2017 - Message Lipid Lowering Treatment • Evidence was insufficient to assess the effect of 5 years of statin … improvement in executive/attention/ processing speed with placebo treatment that was not found with statin … no benefit on brief cognitive test performance, executive/attention/processing speed, or memory for statin … plus fenofibrate versus statin plus placebo in adults with normal cognition.

244. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cognitive-decline_executive.pdf
     March 01, 2017 - Message Lipid Lowering Treatment • Evidence was insufficient to assess the effect of 5 years of statin … improvement in executive/attention/ processing speed with placebo treatment that was not found with statin … no benefit on brief cognitive test performance, executive/attention/processing speed, or memory for statin … plus fenofibrate versus statin plus placebo in adults with normal cognition.

245. HealthyHearts NYC Primary Care Partnerships Advancing Heart Health (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/results/research/recruitment-slides-ny.pdf
     August 18, 2015 - through 79 years of age who had a LDL test performed and who are prescribed a recommended dose of statin

246. Final Progress Report: Rural Trial of Clinic Order Entry With Decision Support (pdf file)
     www.ahrq.gov/sites/default/files/2024-07/samore-report.pdf
     January 01, 2024 - Drug-drug interactions: Overall, 148 coumadin-associated potential drug-drug interactions (DDI), 43 statin-associated … person-months Overall rate Range Overall rate Range across clinics Coumadin DDI 5.5 2.3-20.0 16.3 8.7-29.5 Statin … 100 person-months Overall rate Range rate Overall rate Range Coumadin DDI 9.9 5.1-26.5 12.9 1.7-18.6 Statin … Rate ratio calculated as post CCOE/pre CCOE Rate ratio Range rate ratio Coumadin DDI 1.1 0.4-11.7 Statin

247. H3 Baseline Practice Survey Part 1 (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/results/research/practice-survey-part1-mw.pdf
     June 02, 2025 - practice uses clinical guidelines for management of patients at risk for cardiovascular disease (e.g., statin

248. Palliative Care: Comfort vs. Harm | PSNet
     psnet.ahrq.gov/web-mm/palliative-care-comfort-vs-harm
     December 04, 2016 - In the present case, it was reasonable to withdraw the statin, beta-blocker, and diuretic.

249. View Survey (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/results/research/practice-survey-nw.pdf
     June 02, 2025 - ): Use of Aspirin or Another Antithrombotic NQF 0018 Controlling High Blood Pressure NQF N/A Statin … practice uses clinical guidelines for management of patients at risk for cardiovascular disease (e.g., statin … practice uses clinical guidelines for management of patients at risk for cardiovascular disease (e.g., statin

250. Leveraging Health Information Technology to Avoid Unnecessary Asymptomatic Carotid Revascularization | Digital Healthcare Research
     digital.ahrq.gov/ahrq-funded-projects/leveraging-health-information-technology-avoid-unnecessary-asymptomatic-carotid-revascularization
     January 01, 2023 - obstructive pulmonary disease, smoking, renal failure, contralateral carotid stenosis, and absence of statin

251. Archived: Lipid Disorders in Children: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening-2007
     July 15, 2007 - Benefits of detection and early intervention: a Trials of statin drugs in children with monogenic dyslipidemia

252. Sequist T et al. 2005 "A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease." | Digital Healthcare Research
     digital.ahrq.gov/health-it-tools-and-resources/workflow-assessment-health-it-toolkit/research/sequist-t-et-al-2005
     January 01, 2005 - Sequist T et al. 2005 "A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease." Reference Sequist T, Gandhi T, Karson A, et al. A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary arte…

253. Impact of Health Information Technology on Clinical Care for Patients with Chronic Medical Conditions (pdf file)
     digital.ahrq.gov/sites/default/files/docs/publication/r01hs015280-hsu-final-report-2008.pdf
     January 01, 2008 - mean proportion of days covered by any lipid drugs was 90.8%; among subjects on statins, the mean statin … of more intensive regimens (PDD increased 10.6 mg/day, 95% CI: 10.1-11.2mg/day) among subjects on statin

254. Improving Safety and Quality with Outpatient Order Entry (pdf file)
     digital.ahrq.gov/sites/default/files/docs/publication/r01hs015226-gandhi-final-report-2008.pdf
     January 01, 2008 - Reminders and Guidelines: CAD and elevated LDL— measure LDL if not measured, and start or increase statin … Chronic Disease Management Reminders and Guidelines: DM and elevated LDL—start or increase statin … • Elevated potassium and taking a med that may raise potassium • Elevated ALT and taking a statin

255. Healthy Hearts Northwest Follow-up Practice Survey (#2) (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/results/research/practice-survey-6mon-post-intervention-nw.pdf
     June 02, 2025 - Healthy Hearts Northwest Follow-up Practice Survey (#2) Page 1 CONTINUE TO PAGE 2 Healthy Hearts Northwest is supported by grant number R18HS023908 from the Agency for Healthcare Research and Quality. Healthy Hearts Northwest Follow-up Practice Survey (#2) The first set of questi…

256. PS Grantee | Agency for Healthcare Research and Quality
     www.ahrq.gov/research/findings/final-reports/index.html?page=12
     January 01, 2024 - Grantee Final Reports: Patient Safety Final reports from research grants administered since 2000 on a variety of patient safety topics, such as measure development, medication safety, and diagnostic safety. The Agency for Healthcare Research and Quality Center for Quality Improvement and Patient Safety subdivis…

257. Ch 2-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_2-user-guide-to-ocer_130129.pdf
     January 01, 2011 - selection bias.8, 29, 32 For example, Dormuth et al.32 examined the relationship between adherence to statin … vs. less adherent) and a variety of outcomes thought to be associated with and not associated with statin … as more adherent were less likely to experience negative health outcomes unlikely to be caused by statin … The association between statin use and outcomes potentially attributable to an unhealthy lifestyle … Statin adherence and risk of accidents: a cautionary tale.

258. Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/gXnmnkofo8FxoLnCmXJDjb
     October 01, 2009 - C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.

259. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/2GDCmTe7akyrAHsTMbfz72
     May 06, 2022 - fully conducted prior to 2001, when Adult Treatment Panel III (ATP III) guidelines were published and statin … RCTs that were partly or fully conducted prior to 2001 (when the ATP III guidelines led to widespread statin … Contemporary CVD risk factor management, especially wide- spread statin use, may alter the relative importance … use and found no statistically significant inter- action between aspirin use and statin use.5-7 Nonetheless … Age-related trajectories of cardiovascular risk and use of aspirin and statin among US adults aged 50

260. Draft Research Plan: Enhanced Risk Assessment for Cardiovascular Disease: Coronary Artery Calcium Scoring | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/cardiovascular-disease-enhanced-risk-assessment-non-traditional-risk-factors
     April 25, 2024 - Share to Facebook Share to X Share to WhatsApp Share to Email Print in progress Draft Research Plan Enhanced Risk Assessment for Cardiovascular Disease: Coronary Artery Calcium Scoring April 25, 2024 Recommendations made by the USPSTF are…